Monday
January 20, 2020
Gangnam-gu, South Korea
Fine Dust :
Though British drug maker AstraZeneca has cut back Covid-19 vaccine deliveries across Europe, health authorities in Korea assure the country will have no issues receiving doses from the company within the first quarter of the year.
Prime Minister Chung Sye-kyun said Wednesday that Korea's first batch of Covid-19 vaccines will probably be enough to inoculate 50,000 people.
SK Bioscience has received a contract to locally distribute five vaccines from GlaxoSmithKline (GSK), the Korean company said Wednesday.
SK Bioscience’s coronavirus vaccine candidate was selected to receive $100 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI), the company said Wednesday.
SK Bioscience’s Covid-19 vaccine candidate NBP2001 has received permission to begin Phase 1 clinical trials. The ministry also gave the green light to Phase 2 clinical trials for Dong Wha Pharm’s Covid-19 treatment candidate, DW2008S.
President Moon Jae-in on Thursday pledged the government’s full support of the pharmaceutical industry’s efforts to develop a vaccine and cure for Covid-19.
Bill Gates, co-founder of Microsoft and co-chair of Bill & Melinda Gates Foundation, recently sent a letter to President Moon Jae-in expressing his opinion that Korea may grab a leading spot in developing a coronavirus vaccine.
SK Bioscience will start procedures to go public on the stock market next year, the company said Sunday.
SK Bioscience has been selected as one of the global suppliers for Cambridge, Britain-based AstraZeneca’s Covid-19 vaccine candidate, AZD1222.
Two Korean companies KT and SK Bioscience have received research and development (R&D) funding worth several million dollars from the Bill & Melinda Gates Foundation.
Korea JoongAng Daily Sitemap
